New Strong Buy Stocks for October 14th
NATL, BGC, CCNE, FRME and UVSP have been added to the Zacks Rank #1 (Strong Buy) List on October 14, 2026.
zacks.com · 4h ago
Market movers for the precision investor.
Track top gainers, losers and the most active tickers alongside social signals and breaking market news — all in one clean view.
“Time is on your side when you own shares of superior companies.”
$346.90
+2.05% Today
P/E Ratio
62.02
Market Cap
$14.21B
Beta
0.85
Volume
662.5K
The Social Signal score tracks how much a stock is being discussed across Reddit, 4chan, X, financial news, podcasts and YouTube — a measure of attention, not a recommendation. See the full leaderboard →
Today's movers
Top gainers, losers and the most actively traded tickers.
Top Gainers
Top Losers
Insights
Breaking market news across our tracked coverage.
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
MALVERN, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the execution of a licensing agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen's novel modifier gene therapy for the treatment of Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region.
globenewswire.com · 4h ago
GoldMining Appoints Project Director to Lead Next Phase of Advancement of the São Jorge Gold Project, Brazil
VANCOUVER, BC, Oct. 14, 2026 /PRNewswire/ -- GoldMining Inc. (the "Company" or "GoldMining") (TSX: GOLD) (NYSE American: GLDG) is pleased to announce the appointment of Alexandre Soares Pimenta as Project Director for its 100%-owned São Jorge Gold Project ("São Jorge" or the "Project"), located in Pará State, Brazil. Mr. Pimenta will lead the advancement of the Project, including the commencement of pre-feasibility activities and infill diamond drilling designed to support further evaluation and development planning.
prnewswire.com · 4h ago
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
– Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin Syndrome in Europe after receipt of marketing authorization in the European Union – Designation Represents Eighth Important Regulatory Milestone for QRX003 – QRX003 has also been granted Pediatric Rare Disease Designation and Fast Track Designation for Peeling Skin Syndrome from US Food and Drug Administration – In Netherton Syndrome, QRX003 has been granted Orphan Drug Designation in US, Europe and Japan as well as Pediatric Rare Disease and Fast Track Designations in the US ASHBURN, Va., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
globenewswire.com · 4h ago
Silverco Mining Intercepts 1,280 g/t Silver over 3.35 Metres True Width at Its 100%-Owned Cusi Mine in Chihuahua, Mexico
Vancouver, British Columbia--(Newsfile Corp. - October 14, 2026) - Silverco Mining Ltd. (TSXV: SICO) (OTCQB: SICOF) ("Silverco" or the "Company") is pleased to report further significant intercepts on fifteen holes from its ongoing 30,000 metre drill program at its 100% owned Cusi Property ("Cusi") in Chihuahua, Mexico.
newsfilecorp.com · 4h ago
Kennametal to Host Earnings Conference Call & Webcast on First Quarter Fiscal 2027 Results
PITTSBURGH, Oct. 14, 2026 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) will host its first quarter fiscal year 2027 earnings call on Wednesday, November 4, 2026. The press release and presentation will be available on the Company's website before market on November 4.
prnewswire.com · 4h ago